Compare IXHL & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IXHL | FORA |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Computer Software: Prepackaged Software |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 69.4M |
| IPO Year | N/A | N/A |
| Metric | IXHL | FORA |
|---|---|---|
| Price | $0.43 | $2.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.8M | 36.0K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,000.00 | ★ $28,106,911.00 |
| Revenue This Year | N/A | $47.82 |
| Revenue Next Year | N/A | $10.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $0.08 | $1.64 |
| 52 Week High | $2.25 | $4.03 |
| Indicator | IXHL | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 46.57 |
| Support Level | $0.35 | $2.10 |
| Resistance Level | $0.50 | $2.20 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 68.63 | 55.00 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.